#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Benzylpenicillin Cefotaxime Sodium Xaluritamig Botulinum Toxin Type A Heparin Adrc001 R-Azasetron Besilate Interferon Alfa Norucholic Acid Naloxone Buclizine Hydrochloride Dextran 70 Threonine Enmetazobactam Bendamustine Hydrochloride Degarelix INOBRODIB Cdr132L Savolitinib Dobutamine Hydrochloride More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Sonelokimab
    Belgium Bulgaria Czechia France Germany Hungary +7

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

    Recruiting

    3 1
    Investigated drugs:
    • Bi 1291583
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated drugs:
    • Arginine Hydrochloride
    • Lysine Hydrochloride
    • Metoclopramide Hydrochloride
    France Germany Hungary Italy The Netherlands Poland +1

  • Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Rilvegostomig
    • Tremelimumab
    • Atezolizumab
    France Germany Italy The Netherlands Poland Spain

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated diseases:
    • Crohn’s disease
    Investigated drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    Investigated drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Docetaxel
    Belgium France Germany Ireland Italy The Netherlands +2

  • Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

    Recruiting

    2 1
    Belgium Bulgaria Czechia Hungary Italy Poland +1

  • Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients

    Recruiting

    3 1
    Investigated drugs:
    • Ruxolitinib
    Bulgaria France Germany Italy Poland Spain

  • Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Bevacizumab
    • Trastuzumab Deruxtecan
    Austria Belgium Bulgaria Czechia Denmark France +8
Previous Page
1 … 9 10 11 12 13 … 65
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!